Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07424833 · ClinicalTrials.gov registry record · Phase 1
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
A Phase 1 study, sponsored by Ascentage Pharma Group.
- Not yet
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
NCT07424833: Clinical Trial Phase 1 study, sponsored by Ascentage Pharma Group.
NCT07424833 is a Phase 1 study that has not yet begun recruiting, run by Ascentage Pharma Group. The registered enrollment target is 180 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (200% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07424833, a Phase 1 study, has not yet begun recruiting, sponsored by Ascentage Pharma Group.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
Primary Outcome
A DLT is defined as any treatment-related adverse event (TRAE) meeting protocol-specified toxicity criteria occurring during the DLT evaluation period (Cycle 1). DLTs will be assessed in participants receiving escalating dose levels of APG-3288 to evaluate its safety and tolerability.
Interventions
- DRUG APG-3288
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-03 |
| Est. Completion | 2031-12 |
| Phase | Phase 1 |
What is known before NCT07424833 opens enrollment
NCT07424833 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (200% higher).
The record links to 0 conditions, and to 1 intervention - of which APG-3288 is the first listed.
NCT07424833 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07424833 about?
NCT07424833 is a clinical study titled "A Study of APG-3288 in Relapsed/Refractory Blood Cancers". This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
What is the current status of trial NCT07424833?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2026-03. Estimated completion is 2031-12.
What interventions are being tested in trial NCT07424833?
The interventions under investigation include: APG-3288 (DRUG).
Who is sponsoring clinical trial NCT07424833?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07424833's enrollment target sits among peer trials
180 299th of 2000 higher than 1,690 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia